SMO and skin basal cell carcinoma: As a therapeutic strategy for SMO inhibitor-resistant tumors, several GLI1 inhibitors, such as JQ1 [138], Glabrescione B (GlaB) [139], and arsenic trioxide (ATO) [140], have been developed and tested using in vitro or in vivo models of BCC.